More than 2 million people in the United States have type 1 diabetes mellitus. Pancreatic transplantation has emerged as the single most effective means of achieving normal glucose homeostasis in this patient population. Newer immunosuppressive agents and surgical techniques continue to evolve, resulting in improved longterm graft and patient survival. Herein, an understanding of the evaluation, technical aspects, and perioperative management of pancreas transplantation is outlined.
In the 1920s, insulin was hailed as the cure for diabetes. Nowadays, type 1 diabetes mellitus (DM) affects more than 2 million people in the United States, with about 30,000 new cases diagnosed each year [1] . Type 1 DM is associated with a high morbidity and premature mortality due to complications. Treatment for type 1 DM requires intensive insulin administration to control blood glucose, is labor intensive, is difficult to implement for most patients, and is limited by episodes of hypoglycemia. Pancreatic transplantation is the only treatment of type 1 diabetes that restores insulin secretion and establishes long-term normoglycemia. Therefore, pancreatic transplantation has now become an accepted treatment modality for patients with type 1 DM to control glucose metabolism and prevent complications of diabetes [2] [3] [4] [5] [6] .
Type 1 diabetic patients have complications related to macrovascular disease: (1) coronary artery disease, (2) peripheral vascular disease, and (3) stroke. Diabetes remains a strong independent risk factor for cardiovascular disease. Microvascular complications account for (1) retinopathy, the leading cause of blindness; (2) diabetic nephropathy, the leading cause of end-stage renal disease in the United States [7] ; and (3) diabetic neuropathy, which is a chronic and disabling complication. Renal transplantation offers an improvement in long-term survival and quality of life when compared with dialysis [5, [7] [8] [9] [10] . Increasingly, pancreas transplantation is also being offered to patients who require a kidney transplant, as a simultaneous kidney-pancreas transplant (SKP), or to patients who have had a previous successful kidney transplant, sequential pancreas after kidney transplant (PAK) [2] [3] [4] [5] [6] . The addition of pancreatic transplantation prolongs life in type 1 diabetic patients with renal failure compared with renal transplantation alone [9] . Patient survival at 1, 3, 5, and 8 years was 96%, 93%, 89%, and 77%, respectively, after SKP and 93%, 75%, 57%, and 47%, respectively, after kidney transplant alone. Successful pancreas transplantation results in normalization of blood glucose and glycosylated hemoglobin levels. It also eliminates the need for many dietary restrictions and for exogenous insulin administration. The 1-year patient survival rate is more than 94% in all categories of pancreas transplantation [11] [12] [13] [14] (Figs 1A,  1B ). Contemporary pancreas graft survival rates are 83% and 78% for SKP and PAK or pancreas transplant alone (PTA) transplants, respectively [11] ( Fig  1C) . Overall improvement in quality of life and return to a more normal lifestyle are evident early on [15] . Pancreas transplantation may also be offered to carefully selected nonuremic type 1 dia-betic patients [16] [17] [18] . Pancreas transplantation should be considered as therapy only in patients who exhibit these 3 criteria: (1) a history of frequent, acute, and severe metabolic complications (hypoglycemia, hyperglycemia, ketoacidosis) requiring medical attention; (2) clinical and emotional problems with exogenous insulin therapy that are so severe as to be incapacitating; and (3) consistent failure of insulin-based management to prevent acute complications [13] . Long-term benefits include improvement in autonomic and peripheral diabetic neuropathy and prevention of diabetic nephropathy in renal allograft [2, [11] [12] [13] [14] [15] [16] [17] . In this review, the evaluation of candidates for pancreatic transplantation with emphasis on perioperative management is outlined.
Historical Perspective
Kelly et al [19] performed the world's first clinical pancreas transplant in 1966 at the University of Minnesota in a uremic diabetic patient ( Table 1) . The initial experience with pancreas transplantation from 1966 to the 1980s was marked by low success rate and high mortality rates. The initial results were poor, with 1-year graft and patient survival rates of 21% and 67%, respectively [20] [21] [22] . These were due to the ongoing refinement in the surgical techniques and rather poor immunosuppressive agents available [23] [24] [25] . With the advent of cyclosporine in the early 1980s, the improved results of pancreas transplantation have caused a resurgence in the interest in the procedure. Since then, more than 16,000 such procedures have been recorded in the International Pancreas Transplantation Registry (IPTR) to date [11, 12] . In 2000 alone, the registry recorded more than 1000 procedures in the United States ( Fig 1A) , 8% of which involved just the pancreas. The 1-year patient survival rate was greater than 95%. The 1-year pancreas-graft survival rates were 83% after SKP, 79% after PAK, and 78% with pancreas alone [11, 26, 27] . The majority of deaths were due to cardiovascular disease and usually occurred more than 3 months after discharge from the hospital. The number of pancreas transplants performed with enteric drainage is increasing, with more than 50% of cases since 1998 compared to 30% in 1994-1997 [28] [29] [30] [31] [32] . In the recent past, SKP from a living related donor is gaining popularity [33] [34] [35] [36] [37] . Zielinski et al reported that 1-year patient and renal and pancreatic graft survival rates were 100%, 100%, and 83%, respectively, with no major surgical complications [35] .
Benefits of Transplantation
Successful transplantation restores blood glucose levels and insulin response to glucose load. Hypoglycemia is countered with glucagon and epinephrine release [38, 39] . However, in long-standing type 1 diabetic patients, hypoglycemic hormonal counterregulation and symptom recognition were not restored by intrahepatic islet transplantation [40] . The accumulated data clearly demonstrate that pancreas transplantation decreases mortality, improves quality of life, and gradually reverses the Journal of Intensive Care Medicine 19(3); 2004 2 0 0 0 1 9 9 8 1 9 9 6 1 9 9 4 1 9 9 2 1 9 9 0 [26, 27, [41] [42] [43] [44] [45] [46] . The effect on retinopathy is less clear, but stabilization of the proliferative component is seen and maintained with metabolic control achieved by SKP [43] . Pancreas transplantation can prevent recurrent diabetic nephropathy in transplanted kidneys [41, 44] . If applied early enough in the course of diabetic nephropathy, renal function may be preserved by pancreas transplantation [9, 10] . The favorable effect of pancreas transplantation on diabetic neuropathy has been clearly documented using tests of nerve conduction velocity and action potential amplitude [4] . In regard to vascular disease, favorable findings for atherosclerotic risk factor reduction have been reported after SKP. Improved survival is noted in type 1 diabetic patients after SKP versus those with either a kidney transplant or on the waiting list [44] . PTA with portal drainage induces an early improvement of cardiac risk factors and ameliorates cardiac function in patients with type 1 DM [42] [43] [44] [45] [46] . In summary, pancreas transplantation is the prescription of choice for patients with type 1 DM.
Recipient Evaluation
The indications and contraindications for pancreas transplantation are outlined in Table 2 . The pretransplant evaluation determines whether a patient is an appropriate candidate for transplantation. The organ(s) may originate either from a deceased or living donor or a combination of the two. It is not unusual for patients needing both a kidney and pancreas transplant to get the kidney transplant from a living donor and then await a deceased donor pancreas. Patients may also receive an SKP living-donor transplant in the same operative procedure or a living-donor kidney and a deceased donor pancreas in the same procedure [47] . Type 1 DM is more common among non-Hispanic whites, followed by African Americans and Hispanic Americans. Type 1 DM accounts for 5% to 10% of all diagnosed DM. About 40% of patients with type 1 DM are younger than 20 years at onset. The incidence of the disease appears to be increasing by 3% to 5% per year [1] . Type 1 DM peaks at 2, 4 to 6, and 10 to 14 years, perhaps due to changes in the pattern of infections or increases in insulin resistance [48] . The incidence decreases in people in their 30s, only to increase again in the fifth decade of life, when it tends to present in a less aggressive manner, that is, early hyperglycemia without ketoacidosis.
Candidates for pancreas transplantation are usually young (25-45 years of age) type 1 diabetic patients with end-stage renal disease who need or have previously received a successful renal allograft. In a small number of patients, PTA is considered in individuals who have severe, frequent hypoglycemia, sometimes as a result of autonomic neuropathies [13] . It may also be undertaken in selected patients with evidence of diabetic nephropathy. Therefore, a history of juvenile onset, past ketoacidosis, usually a lean body habitus, and a requirement for 0.3 to 1.0 U/kg of insulin daily are consistent with this diagnosis of type 1 DM. Adult onset, often obesity, and periods of insulin independence or extraordinary insulin requirements may suggest a diagnosis of type 2 DM. Diagnostic uncertainty should be resolved by the administration of a 100-g oral glucose challenge, followed 1 hour later by simultaneous measurement of a blood C-peptide and glucose. A type 1 diabetic person will have undetectable C-peptide levels despite maximal stimulation of the pancreas with simultaneously elevated blood glucose. Conversely, a person with type 2 DM will have blood insulin levels that are normal or elevated as a result of insulin resistance. To determine whether the individual has type 1 rather than type 2 DM, an insulin and/or C-peptide level less than 5 mU/mL or 0.6 ng/mL suggests type 1 DM [48] . C-peptide is formed during conversion of proinsulin to insulin. A high positive titer of glutamic acid decarboxylase antibodies also suggests type 1 DM. An exception is the individual with type 2 DM who presents with a very high glucose level, for example, greater than 300 mg/dL, who temporarily has a low insulin and/or C-peptide level but who will recover insulin production once normal glucose is restored. The presence of nephrotic-range proteinuria (3.5 g/24 h), a creatinine clearance of less than 50 ml/min per 1.73 m2, and a renal biopsy showing diabetic changes are contraindications to pancreatic transplantation alone [10, 13, 17, 22] . These changes are suggestive of advanced renal disease and will require a kidney-pancreas transplant. The presence of asymptomatic coronary artery disease in diabetic patients limits long-term survival; therefore, all candidates older than 30 years or those with the disease for more than 20 years should undergo stress testing, with cardiac catheterization in those with symptoms or equivocal stress test [3, 9, 10] . Impairment of left ventricular function is frequent in patients with type 1 diabetes in the absence of ischemia, hypertension, or valvular heart disease [48] . Possible mechanisms for diabetic cardiomyopathy include abnormalities of small intramural coronary vessels, deposition of collagen, and lipid and metabolic derangements. Signs of peripheral arterial occlusive disease should be carefully elicited. The presence of aortoiliac occlusive disease that can compromise arterial inflow to the transplants may require pretransplantation vascular intervention such as pulse volume recordings or magnetic resonance angiography. The remainder of the evaluation is similar to other solid organ transplants including metabolic, neurological, ophthalmological, renal, and psychiatric evaluations. Diabetic patients are at increased risk during surgery because of heart disease, sepsis, impaired wound healing, negative nitrogen balance, electrolyte disturbances, and renal failure. Meticulous anesthetic and metabolic care should be provided. General anesthesia and surgery increases the secretion of cortisol, catecholamines, glucagon, and growth hormone; this has an adverse effect on blood glucose levels. During general anesthesia, the patient is fasting and unconscious; therefore, particular care must be taken to prevent hypoglycemia.
Donor Evaluation
As a general rule, ideal pancreas donors are younger than 55 years, not obese, hemodynamically stable, nondiabetic, and normoglycemic [12, 22] . Our center uses 55 years of age as the upper limit because there is evidence that the β cell mass begins to decrease after this age. Some centers have also limited donation to people older than 8 years of age or those above a minimum weight of 30 kg [20] [21] [22] [23] [24] . Below this size, vascular reconstruction of the pancreas is very difficult and the risk of thrombosis is unacceptably high [20] [21] [22] [23] [24] [25] 28] .
Management of organ donor includes aggressive resuscitation for hemodynamic stability, organ perfusion, and oxygenation. The retrieved organ is placed in sterile cold storage solution (University of Wisconsin). A cold ischemia time of less than 24 hours is preferred for optimal long-term graft survival. Although preprocurement characteristics associated with a poor outcome may be present, the only certain way to determine the adequacy of a pancreas is to visualize the organ directly at the time of procurement. A normal pancreas is pliable, free of fat in the interlobular septa, shows no evidence of fibrosis from past pancreatitis, and is salmon pink.
Surgical Technique
Pancreatic transplant surgery may last 3 to 5 hours depending on whether it is a PAK, SKP, or PTA. The recipient's native pancreas and kidney are left in [24, 29, 49] . The advantages and disadvantages of each technique are outlined in Table  3 . Bladder drainage results in irritation of the bladder and urethra leading to infections, bleeding, and strictures [50] [51] [52] . In 15% to 25% of cases, conversion to enteric drainage may be warranted due to recurrent urinary tract infections, severe metabolic acidosis, and reflux pancreatitis. Since 1998, two thirds of pancreas transplants used the enteric method for drainage. The enteric drainage procedure, however, has a higher technical failure rate (8% vs 11%) [32, 50, 53] .
The decision to use portal instead of systemic venous drainage is related to a desire to achieve normal peripheral insulin levels in the recipient and lower serum lipid levels [34] . The technique of systemic venous drainage involves anastomosis of the donor portal vein to the recipient iliac (common or external) vein or vena cava (Figs 2A,  2B ). If the recipient has had multiple upper abdominal operations, a foreshortened mesentery, or a prior failed SKP, then systemic venous drainage may be preferred [50] [51] [52] . Portal venous drainage, a more physiologic method that eliminates hyperinsulinemia, is gaining interest among pancreas transplant centers. Recently published studies have shown no statistical difference with systemic bladder or enteric drainage in either patient or allograft survival [50, 54] . Since its initial description in 1984, portal venous drainage of pancreas allograft underwent several technical modifications. At our institu-tion, we have adopted the Roux-en-Y venting jejunostomy [52] , described in detail in previous publications, in portal-enteric drainage for pancreatic transplantation to monitor rejection and prevent anastomotic leaks with good success (Fig 2C) [31].
Postoperative Period

Early Postoperative Period
Patients are monitored in the surgical intensive care unit for the initial posttransplant period. Regimens used to prevent vascular thrombosis of allograft include oral aspirin (81 mg/d) along with 3000 to 5000 units of intravenous heparin during the surgery [48] . Subcutaneous dalteparin (used in our center) and low molecular weight dextran may also be used. Duplex ultrasonography is routinely performed on the first postoperative day and as needed afterward to assess flow and function in allograft. Intravenous insulin infusion may be administered to maintain euglycemia. An acute rise in serum glucose levels or persistently elevated levels above 200 mg/dL require prompt evaluation with duplex ultrasonography to assess allograft perfusion and function. Other parameters that are closely monitored include urinary, serum, and ostomy amylase levels. Muromonab-CD3 levels and calcineurin inhibitor levels (cyclosporine, tacrolimus) are also monitored. The causes of allograft dysfunction are Oral pancreatic enzymes may be used for malabsorption in the initial postoperative period. Surgical complications are seen in 30% to 40% of cases [2, 11, 12] . The majority of complications (Table 5 ) are anastomotic leaks after bladder or enteric drainage, wound infections, graft thrombosis, and infections [55] [56] [57] . Early thrombosis, usually within 48 hours of surgery, is the most common cause of nonimmunologic graft loss in the first year [2, 11, 12] . Thrombosis is heralded by a sudden rise in blood glucose. Several radiological methods such as Doppler ultrasound, computed tomography (CT) scans, and magnetic resonance angiography may be employed for investigating the transplanted allograft [48] . Confirmation is usually obtained with duplex ultrasound. Treatment is the immediate removal of the transplant pancreas. Diabetic patients have a relative hypercoagulable state, in part because of defective fibrinolysis. In contrast, recipients of solitary pancreas transplants are nonuremic and consequently have an 8% incidence of early thrombosis [2, 11, 12] . To avoid this complication, some centers treat recipients with a continuous low-dose heparin infusion, followed by warfarin anticoagulation. Monitoring of serum amylase and lipase is used to detect rejection. In bladder-drained patients, the urinary amylase and lipase are more specific markers [50, 52] . The diagnosis of rejection is best confirmed with percutaneously obtained biopsy material that demonstrates the classic findings of renal or pancreatic rejection [58] [59] [60] . With SKP transplants, monitoring the serum creatinine can prompt detection of rejection episodes with renal biopsy. Clearly, acute rejection episodes have a negative impact on the long-term kidney graft survival in the SKP population similar to that in the cadaver kidney transplants. Patients who had acute rejection episodes of both kidney and pancreas have the worst long-term graft survival [60] . The diagnosis of acute rejection in enteric drainage will depend on clinical markers of pancreatic and/or renal function and needle biopsy. Indications for pancreatic biopsy included hyperamylasemia, hyperlipasemia, hyperglycemia, or unexplained fever [58] [59] [60] . Hyperglycemia may be due to preexisting patient insulin resistance exacerbated by known effects on insulin action and/or secretion even in usual concentrations. Moreover, the histologic picture of calcineurin inhibitor toxicity is distinguishable only by biopsy. Leakage of pancreatic secretions is usually more commonly seen with bladder drainage procedures rather than enteric drainage ones. Aspiration of secretions with CT-guided drainage-and in some cases, surgical exploration with revision-may be needed. Octreotide, a somatostatin analogue, has been used in such cases with success.
Infectious Complications
Diminished manifestations of infection are seen in the transplant recipient. The use of radiological tests (CT scan, magnetic resonance imaging) is essential along with tissue histology to work up unexplained fevers. Unexplained fever may be the result of a number of infectious causes. Cytomegalovirus (CMV) infection may be seen at any time after transplant, but the most common period is 1 to 4 months posttransplant (Fig 3) . The clinical manifestations of the CMV syndrome are characterized by fever and laboratory abnormalities (leukopenia, thrombocytopenia, mild transient hepatitis). Severe disease will have persistent fever along with possible pneumonia, gastrointestinal ulcers, hepatitis, myocarditis, elevated serum creatinine in transplants, and pancreatitis. Treatment remains intravenous ganciclovir, as resistant cases are rare. Ganciclovir-resistant CMV cases are seen more commonly in SKP and lung transplants recipients. These cases are treated with intravenous foscarnet and cidofovir. Newer oral agents such as valganciclovir, with superior bioavailability and less resistance, may offer an improvement over current choices [61] . The polyoma BK virus may be reactivated in transplant recipients causing hemorrhagic cystitis, acute rejection, and ureteral stenosis. It may lead to allograft loss in certain cases [61] . Pulmonary infections are also common posttrans-plant. Focal or multifocal consolidation are likely bacterial. Similar lesions with a progressive nature are more likely to be fungal or tuberculous. Subacute diffuse pulmonary process is usually viral. Cavitary lesions suggest fungal, nocardial, and gram-negative causes (Klebsiella pneumoniae or Pseudomona aeruginosa). The presence of fever with signs of central nervous system involvement is an emergency. Four distinct patterns of infection exist: (1) acute meningitis due to Listeria monocytogenes (2) subacute to chronic meningitis over days to weeks due to Cryptococcus neoformans or other less common agents such as M. tuberculosis and Nocardia, (3) focal brain infection presenting as seizures most commonly due to metastatic Aspergillus, and (4) progressive dementia due to progressive multifocal leukoencephalopathy by the JC virus. Another complication is peripancreatic sepsis, caused by organisms inoculated into the peritoneal cavity. The patient has persistent ileus, fever, abdominal pain, leukocytosis, and tenderness between 7 and 14 days after surgery. Treatment includes abdominal lavage, debridement of necrotic peripancreatic fat, and antibiotics. Prolonged attempts to treat with antibiotics may lead to fungal peritonitis. If leakage occurs, an attempt at anastomotic revision is warranted, but removal of the pancreas may ensue with treatment failure. Occasionally, a very late (> 30 days) presentation of an infected, discrete fluid collection can be resolved with catheter drainage. Complications requiring laparotomy result in increased mortality.
Metabolic Complications
Hyperinsulinemia seen after transplant is attributed to numerous factors such as diminished insulin clearance by the liver, immunosuppressive drugs, denervation of the transplanted pancreas, and insulin resistance. Use of steroids and calcineurin inhibitors (cyclosporine, tacrolimus) are potentially diabetogenic.
Immunosuppression
Induction therapy with polyclonal and monoclonal antibodies has shown delayed and reduced severity of rejection episodes [62, 63] (Table 6) . Thymoglobulin, a polyclonal rabbit-derived antilymphocyte antibody, was originally introduced to treat acute rejection. However, in the recent past, it appears to yield graft survival results comparable to more potent regimens. As such, the consensus now is to use a quadruple drug regimen including polyclonal or monoclonal anti-T cell antibody, mycophenolate mofetil (MMF), tacrolimus (FK506), or cyclosporine (CsA), and a rapid steroid taper [64, 65] . The protocols used for maintenance immunosuppressive therapy in the United States are outlined in Figure 4 . Most transplant programs use the monoclonal antibody to measure CsA levels. Due to the nephrotoxic potential of calcineurin inhibitors, initiation of CsA/FK506 is delayed until the second or third postoperative day when glomerular filtration rate and urine flow is well established. A variety of potentially serious problems have been linked to CsA, namely, hypertension, microangiopathic hemolytic anemia, and chronic renal dysfunction. Monitoring of CsA/FK506 levels is therefore recommended. Side effects noted to be significantly higher in transplant recipients receiving FK506 versus CsA were neurological complications of tremor and paresthesia. Diabetes may be seen more commonly in patients using FK506 due to its potential islet cell toxicity. In a recently conducted trial, no significant difference was noted between CsA and FK506 with regard to patient and allograft survival [66] . The most common maintenance immunosuppressive regimen consists of FK506 and MMF for SKP (Fig 4) .
SKP recipients receiving chronic low-dose cyclosporine maintenance compared to cyclosporinefree recipients had similar glucose levels. Nonetheless, this is obtained at the expense of a higher endogenous insulin secretion, which can cause an alteration of the triglyceride profile [67] . The introduction of doclizumab (Zenapax), basiliximab (Simulect), and antithymocyte globulin have provided less toxic drugs for induction therapy [62] [63] [64] [67] [68] [69] . A large multicenter trial of 174 patients to determine the role of induction therapy (with standard immunosuppressive) in SKP transplantation showed no statistically significant differences between treatment groups for patient, kidney, and pancreas graft survival at 1 year [63] . Daclizumab and basiliximab are safe and effective in reducing the incidence of acute rejection in SKP recipients compared with no antibody induction [64] . The substitution of azathioprine by MMF has reduced the rejection rates for SKP [70, 71] . MMF is combined with either tacrolimus or cyclosporine [72] . The use of the newer cell cycle inhibitor rapamycin (sirolimus) in pancreas transplantation produced good results with low rates of acute rejection and opportunistic infections [62] . Rapamycin use is also seen as a replacement or rescue therapy for patients experiencing unacceptable toxicity with standard agents [73] [74] [75] .
The use of rapamycin as a maintenance agent is rising as it was used in more than 400 patients in the past 3 years. Long-term studies regarding its use are currently under way. Preoperative antibiotic prophylaxis consists of imipenem or cephazolin intravenously. Other agents used preoperatively and postoperatively are listed in Table 7 .
Future Trends
Islet cell transplantation now provides low morbidity transplantation before the onset of diabetic complications [76] . Infused through the portal vein, the islet cells seed the patient's liver and remain viable for more than a year in those receiving more than 300,000 islet cells. The result of the Edmonton group study is a milestone achievement. The results have since been duplicated in the United States and Europe [65, 77] .
With the limitation of human tissue, many are exploring the possibility of using tissue from other species. A variety of potential species have been proposed, including pigs, cows, rabbits, rodents, Journal of Intensive Care Medicine 19 (3) and even fish. Pigs have had particular appeal, in part because human and pig insulin are almost identical, as well as the similarity between porcine and human blood-glucose levels. Because pigs are part of the food chain, people tend to be comfortable with the prospect of using this source. Much work is now being done to develop ways to use either fetal or neonatal islet tissue, both of which are attractive sources because of their growth potential. One of the problems with this tissue is that the cells are immature, which means they are less efficient in normalizing glucose levels rapidly in recipients. Another potential problem is that porcine tissue contains retroviruses that can be transferred to human cells in tissue culture. Preliminary results of experimental mice suggest that kidneys created from human and pig stem cells might one day be used for human transplants [78] .
Summary
Currently, the best option for type 1 diabetic patients remains tight glucose control and prevention of its complications. With recent advances in surgical techniques and immunosuppressive drugs, the morbidity and mortality associated with pancreatic transplantation continues to decline. Pancreas graft survival has consistently improved in all recipient categories, namely, SKP, PAK, and PTA, with 1-year graft survival of 84%, 76%, and 77%, respectively [79] . The focus remains on developing more efficacious and less toxic immunosuppressive agents for the future. 
